e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Environmental exposure and disease mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adipokine adipsin is associated with the degree of parenchymal fibrosis in asbestos-exposed patients
S. Leivo-Korpela, L. Lehtimäki, R. Nieminen, P. Oksa, T. Vierikko, R. Järvenpää, J. Uitti, E. Moilanen (Tampere, Finland)
Source:
Annual Congress 2011 - Environmental exposure and disease mechanisms
Session:
Environmental exposure and disease mechanisms
Session type:
Poster Discussion
Number:
3318
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Leivo-Korpela, L. Lehtimäki, R. Nieminen, P. Oksa, T. Vierikko, R. Järvenpää, J. Uitti, E. Moilanen (Tampere, Finland). Adipokine adipsin is associated with the degree of parenchymal fibrosis in asbestos-exposed patients. Eur Respir J 2011; 38: Suppl. 55, 3318
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Imaging of eosinophilic lung disease
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Leptin and adiponectin levels in idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Increased CCL18 production in interstitial lung diseases is associated with fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 38s
Year: 2004
Circulating inflammatory cytokines in adult cystic fibrosis patients
Source: Annual Congress 2009 - Cystic fibrosis: advances in clinical research
Year: 2009
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity
Source: Eur Respir J 2005; 26: Suppl. 49, 21s
Year: 2005
Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
KL-6 serum levels in adult cystic fibrosis patients
Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies
Year: 2011
Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
Pleural pathology and lung fibrosis in patients with retroperitoneal fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 146s
Year: 2004
Increased polysialylation in lung tissue of patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2011 - Cell biology of lung disease
Year: 2011
Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011
Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Increased cytokeratin-19 expression in fibrotic interstitial lung disease
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2014 – ILDs 1
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept